Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer treatment, has announced inducement grants under its 2022 Employment Inducement Incentive Award Plan. The company granted stock options for 381,000 shares to six new employees.
The options, priced at $1.72 per share, will vest over four years with 25% vesting in the first year and the remaining 75% vesting monthly over three years. These grants, approved by the Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent to the company.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di un inibitore WEE1 per il trattamento del tumore ovarico, ha annunciato concessioni di incentivi ai sensi del suo 2022 Employment Inducement Incentive Award Plan. L’azienda ha assegnato opzioni su 381.000 azioni a sei nuovi dipendenti.
Le opzioni, con prezzo di esercizio di $1,72 per azione, matureranno in quattro anni: il 25% matura nel primo anno e il restante 75% matura mensilmente nei tre anni successivi. Le assegnazioni, approvate dal Compensation Committee e conformi alla Nasdaq Listing Rule 5635(c)(4), sono pensate per attrarre nuovi talenti.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una compañía biofarmacéutica en fase clínica centrada en desarrollar un inhibidor de WEE1 para el tratamiento del cáncer de ovario, ha anunciado concesiones de incentivos según su 2022 Employment Inducement Incentive Award Plan. La empresa otorgó opciones sobre 381.000 acciones a seis nuevos empleados.
Las opciones, con un precio de ejercicio de $1,72 por acción, se consolidarán durante cuatro años: el 25% se consolida en el primer año y el 75% restante se consolida mensualmente durante los tres años siguientes. Estas concesiones, aprobadas por el Comité de Compensación y conformes a la Nasdaq Listing Rule 5635(c)(4), están diseñadas para atraer nuevo talento.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), 난소암 치료를 위한 WEE1 억제제 개발에 주력하는 임상 단계 바이오제약사로서, 2022 Employment Inducement Incentive Award Plan에 따른 유인 보상(Inducement grants)을 발표했습니다. 회사는 신규 직원 6명에게 381,000주에 대한 스톡옵션을 부여했습니다.
행사가격은 주당 $1.72이며, 옵션은 4년간 베스팅됩니다: 첫해에 25% 베스트되고 나머지 75%는 이후 3년 동안 매월 베스팅됩니다. 이 부여는 보상위원회 승인 하에 Nasdaq Listing Rule 5635(c)(4)를 준수하며, 신규 인재 유치를 목표로 합니다.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), une société biopharmaceutique en phase clinique axée sur le développement d’un inhibiteur de WEE1 pour le traitement du cancer de l’ovaire, a annoncé des attributions d’inducement dans le cadre de son 2022 Employment Inducement Incentive Award Plan. La société a accordé des options sur 381 000 actions à six nouveaux employés.
Les options, au prix d’exercice de 1,72 $ par action, seront acquises sur quatre ans : 25 % seront acquis la première année et les 75 % restants seront acquis mensuellement sur les trois années suivantes. Ces attributions, approuvées par le Compensation Committee et conformes à la Nasdaq Listing Rule 5635(c)(4), visent à attirer de nouveaux talents.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), ein biopharmazeutisches Unternehmen in klinischer Phase, das an einem WEE1-Inhibitor zur Behandlung von Eierstockkrebs arbeitet, hat Inducement-Grants im Rahmen seines 2022 Employment Inducement Incentive Award Plan angekündigt. Das Unternehmen gewährte sechs neuen Mitarbeitenden Aktienoptionen auf 381.000 Aktien.
Die Optionen haben einen Ausübungspreis von $1,72 pro Aktie und werden über vier Jahre unverfallbar: 25% werden im ersten Jahr unverfallbar, die restlichen 75% unverfallen monatlich über die folgenden drei Jahre. Die Zuweisungen wurden vom Compensation Committee genehmigt, entsprechen der Nasdaq Listing Rule 5635(c)(4) und sollen neues Talent anziehen.
- None.
- None.
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on September 2, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 381,000 shares of the Company’s common stock to six (6) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contacts:
Aron Feingold – VP, IR & Corp Comms
ir@zentalis.com
FAQ
What stock options did Zentalis Pharmaceuticals (ZNTL) grant to new employees in September 2025?
What is the vesting schedule for Zentalis (ZNTL) employee stock options granted in September 2025?
What is Zentalis Pharmaceuticals' (ZNTL) main drug development focus?
What is the purpose of Zentalis' (ZNTL) 2022 Inducement Plan?
